245 related articles for article (PubMed ID: 36412685)
21. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
22. Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
Lawal IO; Marcus C; Schuster DM; Goyal S; Adediran OA; Dhere VR; Joshi SS; Abiodun-Ojo OA; Master VA; Patel PR; Fielder B; Goodman M; Shelton JW; Kucuk O; Hershatter B; Halkar RK; Jani AB
Clin Nucl Med; 2023 Apr; 48(4):e153-e159. PubMed ID: 36754362
[TBL] [Abstract][Full Text] [Related]
23. Predictors of
Mena E; Rowe SP; Shih JH; Lindenberg L; Turkbey B; Fourquet A; Lin FI; Adler S; Eclarinal P; McKinney YL; Citrin DE; Dahut W; Wood BJ; Chang R; Levy E; Merino M; Gorin MA; Pomper MG; Pinto PA; Eary JF; Choyke PL; Pienta KJ
J Nucl Med; 2022 Aug; 63(8):1184-1190. PubMed ID: 34916246
[TBL] [Abstract][Full Text] [Related]
24. [
Nappi AG; Ferrari C; Mammucci P; Rubini D; Lavelli V; Sardaro A; Pisani AR; Rubini G
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326614
[TBL] [Abstract][Full Text] [Related]
25. Utility of
Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
[No Abstract] [Full Text] [Related]
26. Phase III Study of
Olivier P; Giraudet AL; Skanjeti A; Merlin C; Weinmann P; Rudolph I; Hoepping A; Gauthé M
J Nucl Med; 2023 Apr; 64(4):579-585. PubMed ID: 36418170
[TBL] [Abstract][Full Text] [Related]
27. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
28. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
England JR; Paluch J; Ballas LK; Jadvar H
Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
[TBL] [Abstract][Full Text] [Related]
29. Positivity Rate of [
Bulbul JE; Grybowski D; Lovrec P; Solanki AA; Gabriel MS; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2022 Feb; 24(1):42-49. PubMed ID: 34480289
[TBL] [Abstract][Full Text] [Related]
30. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
31. Head-to-Head Comparison of [
García-Zoghby L; Lucas-Lucas C; Amo-Salas M; Soriano-Castrejón ÁM; García-Vicente AM
Curr Oncol; 2023 Jun; 30(7):6271-6288. PubMed ID: 37504324
[TBL] [Abstract][Full Text] [Related]
32. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
[TBL] [Abstract][Full Text] [Related]
33.
Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
[TBL] [Abstract][Full Text] [Related]
34. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
35. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
36. Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus
Lawal IO; Jani AB; Adediran OA; Goyal S; Abiodun-Ojo OA; Dhere VR; Marcus CV; Joshi SS; Master VA; Patel PR; Goodman M; Shelton JW; Kucuk O; Hershatter B; Fielder B; Halkar RK; Schuster DM
J Nucl Med; 2023 Apr; 64(4):586-591. PubMed ID: 36328489
[TBL] [Abstract][Full Text] [Related]
37.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
38. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.
Garza D; Kandathil A; Xi Y; Subramaniam RM
Nucl Med Commun; 2021 Aug; 42(8):907-913. PubMed ID: 33741863
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
40. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
